HealthEquity (NASDAQ:HQY) Price Target Raised to $129.00

HealthEquity (NASDAQ:HQY) had its price target hoisted by JPMorgan Chase & Co. from $126.00 to $129.00 in a research report released on Thursday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

Several other research firms have also issued reports on HQY. Citizens Jmp raised their price target on shares of HealthEquity from $117.00 to $122.00 and gave the stock a “market outperform” rating in a report on Thursday. Citigroup reiterated an “outperform” rating on shares of HealthEquity in a report on Thursday. BTIG Research reissued a “buy” rating and issued a $130.00 price objective on shares of HealthEquity in a research note on Thursday. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of HealthEquity in a research note on Wednesday, October 8th. Finally, Wall Street Zen downgraded HealthEquity from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $120.43.

HealthEquity Stock Performance

HealthEquity stock opened at $94.51 on Thursday. The business has a 50 day moving average of $96.37 and a 200-day moving average of $96.82. The company has a debt-to-equity ratio of 0.46, a current ratio of 4.13 and a quick ratio of 4.23. HealthEquity has a 1 year low of $74.07 and a 1 year high of $116.65. The company has a market capitalization of $8.07 billion, a P/E ratio of 43.35, a P/E/G ratio of 1.36 and a beta of 0.18.

HealthEquity (NASDAQ:HQY) last released its quarterly earnings results on Wednesday, December 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $0.11. The firm had revenue of $322.16 million during the quarter, compared to the consensus estimate of $320.92 million. HealthEquity had a net margin of 14.86% and a return on equity of 12.94%. The company’s revenue for the quarter was up 7.2% on a year-over-year basis. During the same quarter last year, the firm earned $0.78 earnings per share. HealthEquity has set its FY 2026 guidance at 3.870-3.950 EPS. On average, equities research analysts predict that HealthEquity will post 2.32 earnings per share for the current year.

Insider Buying and Selling

In other HealthEquity news, EVP Delano Ladd sold 6,000 shares of the company’s stock in a transaction on Friday, September 19th. The shares were sold at an average price of $94.11, for a total transaction of $564,660.00. Following the transaction, the executive vice president owned 79,456 shares in the company, valued at approximately $7,477,604.16. This represents a 7.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Michael Henry Fiore sold 1,781 shares of the firm’s stock in a transaction on Tuesday, October 7th. The shares were sold at an average price of $88.21, for a total transaction of $157,102.01. Following the completion of the transaction, the executive vice president directly owned 49,795 shares in the company, valued at $4,392,416.95. This trade represents a 3.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 10,781 shares of company stock worth $1,016,707 over the last ninety days. 1.50% of the stock is owned by insiders.

Institutional Investors Weigh In On HealthEquity

A number of institutional investors and hedge funds have recently made changes to their positions in HQY. Farther Finance Advisors LLC increased its position in shares of HealthEquity by 232.4% during the 2nd quarter. Farther Finance Advisors LLC now owns 246 shares of the company’s stock valued at $26,000 after purchasing an additional 172 shares during the last quarter. WPG Advisers LLC bought a new stake in HealthEquity in the first quarter worth about $28,000. True Wealth Design LLC boosted its stake in HealthEquity by 3,522.2% in the third quarter. True Wealth Design LLC now owns 326 shares of the company’s stock valued at $31,000 after acquiring an additional 317 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of HealthEquity during the 2nd quarter valued at approximately $33,000. Finally, Cullen Frost Bankers Inc. grew its position in shares of HealthEquity by 172.3% during the 2nd quarter. Cullen Frost Bankers Inc. now owns 354 shares of the company’s stock valued at $37,000 after acquiring an additional 224 shares during the period. Institutional investors and hedge funds own 99.55% of the company’s stock.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.